Skip to content
drillr.ai

TLSI

TriSalus Life Sciences, Inc.

NASDAQ · USHealthcareMedical - Devices
$4.31+0.47%

Price as of Jul 20, 2026

TLSI news

TriSalus Life Sciences, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 27, 2026 / Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether TriSalus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click

    ACCESSWIRE ·

  2. TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm

    LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm (https://www.globenewswire.com/Tracker?data=O02IEUXuC0Z4ZeP9ocu6H-U2ryqRKXwlk4enrUb0oQotjXTc7NeXW3mWAsZsi2tyCdgqiOzt8zeVrl2A51RjNmiHXZiTvRJBOdqhCNr2I1Y=), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life Sciences, Inc. (“TriSalus” or “the Company”) (NASDAQ: TLSI (https://www.globenewswire.com/Tracker?data=bTJwAww_xlbWOJNZXNh4I_xoa8pKROIL_JZQ9OUyO6dksi

    Globe Newswire ·

  3. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TriSalus Life Sciences, Inc. (TLSI) And Encourages Shareholders to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TriSalus Life Sciences, Inc. ("TriSalus" or "the Company") (NASDAQ:TLSI). Investors who purchased TriSalus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TLSI. (https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_

    ACCESSWIRE ·

  4. Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 3, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TriSalus Life Sciences, Inc. ("TriSalus" or "the Company") (NASDAQ:TLSI). Investors who purchased TriSalus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TLSI. (https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_

    ACCESSWIRE ·

  5. Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Investors to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 28, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TriSalus Life Sciences, Inc. ("TriSalus" or "the Company") (NASDAQ:TLSI). Investors who purchased TriSalus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TLSI. (https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_

    ACCESSWIRE ·

  6. TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky

    TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, May 22, 2026 TriSalus Life Sciences Inc. reaffirmed $60-$62 million revenue guidance on March 5, 2026. Months later, the company cut that outlook to $54-$57 million after missing Q1 estimates. NEW YORK, May 22, 2026 /PRNewswire/ -- TriSalus Life Sciences Inc. (TLSI) shareholders lost value after the company slashed its full-year 2026 revenue guidance to $54 million-$57 million -- down from the $60 million-$62

    PR Newswire ·

  7. Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky Today

    New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffir

    Newsfile Corp ·

  8. TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud

    TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud TriSalus Life Sciences Inc. guided investors to $60-$62 million in 2026 revenue on March 5, then slashed that outlook to $54-$57 million months later Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on Mar

    Business Wire ·

  9. Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

    Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz The Law Offices of Frank R. Cruz (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com%2F&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=The+Law+Offices+of+Frank+R.+Cruz&index=1&md5=3ef11fbb481c873bb7af4bb883a85fcf) announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the

    Business Wire ·

  10. Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your Rights

    New York, New York--(Newsfile Corp. - May 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ: TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffi

    Newsfile Corp ·

  11. TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

    TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study desig

    Business Wire ·

  12. TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

    TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April

    Business Wire ·

  13. TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

    TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the r

    Business Wire ·

  14. TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

    TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year Periods Reaffirms 2026 Revenue Guidance of $60-62 million Strengthened Balance Sheet with $46 Million Gross Proceeds from Recent Public Offering Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences,

    Business Wire ·